nach oben

Erschienen in:

04.08.2023 | Original Article

Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma

verfasst von: Chuimian Zeng, Hai Li, Weiwei Liang, Junxin Chen, Yilin Zhang, Hanrong Zhang, Haipeng Xiao, Yanbing Li, Hongyu Guan

Erschienen in: Endocrine | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

StAR Related Lipid Transfer Domain Containing 13 (STARD13) serves as a tumor suppressor and has been characterized in several types of malignancies. However, the role and the molecular mechanism of STARD13 in regulating the progression of papillary thyroid carcinoma (PTC) remain underexplored.

Methods

The gene expression and clinical information of thyroid cancer were downloaded using “TCGAbiolinks” R package. Quantitative PCR and immunohistochemical staining were conducted to detect the expression of STARD13 in clinical tumor and adjacent non-tumor samples. Wound-healing assay, Transwell assay and 3D spheroid invasion assay were performed to evaluate the migratory and invasive capacities of PTC cells. Cell proliferation ability was determined by CCK-8 assay, colony formation assay and 5-ethynyl-2’-deoxyuridine (EdU) incorporation assay. The alterations of indicated proteins were detected by Western blotting.

Results

In the present study, we found that STARD13 was significantly underexpressed in PTC, which was correlated with poor prognosis. Downregulation of STARD13 might be due to methylation of promoter region. Loss-and gain-of-function experiments demonstrated that STARD13 impeded migratory and invasive capacities of PTC cells in vitro and in vivo. In addition, we found that STARD13 regulated the morphology of PTC cells and inhibited epithelial-mesenchymal transition (EMT).

Conclusion

Our results suggest that STARD13 acts as a metastasis suppressor and might be a potential therapeutic target in PTC.

Nur mit Berechtigung zugänglich

H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021)PubMedCrossRef

F. Basolo, E. Macerola, A.M. Poma, L. Torregrossa, The 5(th) edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma. Endocrine 80(3), 470–476 (2023)PubMedPubMedCentralCrossRef

T. Yan, W. Qiu, J. Song, Y. Fan, Z. Yang, ARHGAP36 regulates proliferation and migration in papillary thyroid carcinoma cells. J. Mol. Endocrinol. 66(1), 1–10 (2021)PubMedCrossRef

L. Torregrossa, D. Viola, E. Sensi, M. Giordano, Piaggi, C. Romei et al. Papillary thyroid carcinoma with rare exon 15 BRAF mutation has indolent behavior: a single-institution experience. J. Clin. Endocrinol. Metab. 101(11), 4413–4420 (2016)PubMedCrossRef

H. Guan, Y. Guo, L. Liu, R. Ye, W. Liang, H. Li et al. INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. Cell Biosci. 8, 26 (2018)PubMedPubMedCentralCrossRef

S. El-Sitt, B.D. Khalil, S. Hanna, M. El-Sabban, N. Fakhreddine, M. El-Sibai, DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma. Oncol. Rep. 28(2), 511–8 (2012)PubMedCrossRef

Y. Ching, C.M. Wong, S.F. Chan, T.H. Leung, D.C. Ng, D.Y. Jin et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J. Biol. Chem. 278(12), 10824–30 (2003)PubMedCrossRef

V. Ullmannova, N.C. Popescu, Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int. J. Oncol. 29(5), 1127–32 (2006)PubMed

T.H. Leung, Y. Ching, J.W. Yam, C.M. Wong, T.O. Yau, D.Y. Jin et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc. Natl Acad. Sci. USA 102(42), 15207–12 (2005)PubMedPubMedCentralCrossRef

10.

T.H. Leung, J.W. Yam, L.K. Chan, Y.P. Ching, I.O. Ng, Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway. Liver Int. 30(9), 1315–23 (2010)PubMedCrossRef

11.

F. Gao, X. Yu, R. Meng, J. Wang, L. Jia, STARD13 is positively correlated with good prognosis and enhances 5-FU sensitivity via suppressing cancer stemness in hepatocellular carcinoma cells. Onco Targets Ther. 11, 5371–5381 (2018)PubMedPubMedCentralCrossRef

12.

F. Tang, R. Zhang, Y. He, M. Zou, L. Guo, T. Xi, MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One 7(5), e35435 (2012)PubMedPubMedCentralCrossRef

13.

S. Chang, S. He, G. Qiu, J. Lu, J. Wang, J. Liu et al. MicroRNA-125b promotes invasion and metastasis of gastric cancer by targeting STARD13 and NEU1. Tumour Biol. 37(9), 12141–12151 (2016)PubMedCrossRef

14.

M. Wu, X. Tan, P. Liu, Y. Yang, Y. Huang, X. Liu et al. Role of exosomal microRNA-125b-5p in conferring the metastatic phenotype among pancreatic cancer cells with different potential of metastasis. Life Sci. 255, 117857 (2020)PubMedCrossRef

15.

Y. Lu, W. Zheng, X. Rao, Y. Du, J. Xue, MicroRNA-9-5p facilitates lung adenocarcinoma cell malignant progression via targeting STARD13. Biochem. Genet. 60(6), 1865–1880 (2022)PubMedCrossRef

16.

L. Chen, W. Hu, G. Li, Y. Guo, Z. Wan, J. Yu, Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. Cell Mol. Biol. Lett. 24, 20 (2019)PubMedPubMedCentralCrossRef

17.

X. Xu, S. Zheng, MiR-887-3p negatively regulates STARD13 and promotes pancreatic cancer progression. Cancer Manag. Res. 12, 6137–6147 (2020)PubMedPubMedCentralCrossRef

18.

Y. Qian, Y. Zhang, H. Ji, Y. Shen, L. Zheng, S. Cheng et al. LINC01089 suppresses lung adenocarcinoma cell proliferation and migration via miR-301b-3p/STARD13 axis. BMC Pulm. Med. 21(1), 242 (2021)PubMedPubMedCentralCrossRef

19.

J. Cai, J. Zhao, N. Zhang, X. Xu, R. Li, Y. Yi et al. MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma. J. Biol. Chem. 290(41), 24678–88 (2015)PubMedPubMedCentralCrossRef

20.

W. Liang, H. Guan, X. He, W. Ke, L. Xu, L. Liu et al. Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2. Oncotarget 6(31), 31780–91 (2015)PubMedPubMedCentralCrossRef

21.

A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102(43), 15545–50 (2005)PubMedPubMedCentralCrossRef

22.

W. He, Y. Sun, J. Ge, X. Wang, B. Lin, S. Yu et al. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. Front Endocrinol. (Lausanne) 14, 1076640 (2023)PubMedCrossRef

23.

N. Cancer Genome Atlas Research, Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3), 676–90 (2014)CrossRef

24.

M. Xing, A.S. Alzahrani, K.A. Carson, Y.K. Shong, T.Y. Kim, D. Viola et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J. Clin. Oncol. 33(1), 42–50 (2015)PubMedCrossRef

25.

W. Pu, X. Shi, P. Yu, M. Zhang, Z. Liu, L. Tan et al. Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat. Commun. 12(1), 6058 (2021)PubMedPubMedCentralCrossRef

26.

H. Tang, L. Jiang, C. Zhu, R. Liu, Y. Wu, Q. Yan et al. Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Oncogene 38(17), 3119–3133 (2019)PubMedCrossRef

27.

Z. Miao, Q. Cao, R. Liao, X. Chen, X. Li, L. Bai et al. Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness. J. Exp. Clin. Cancer Res. 41(1), 169 (2022)PubMedPubMedCentralCrossRef

28.

D.S. Chandrashekar, S.K. Karthikeyan, P.K. Korla, H. Patel, A.R. Shovon, M. Athar et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18–27 (2022)PubMedPubMedCentralCrossRef

29.

L. Jaafar, I. Fakhoury, S. Saab, L. El-Hajjar, W. Abou-Kheir, M. El-Sibai, StarD13 differentially regulates migration and invasion in prostate cancer cells. Hum. Cell 34(2), 607–623 (2021)PubMedCrossRef

30.

L. Sun, J. Sun, J.D. Song, High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC. Mol. Med. Rep. 19(6), 4881–4889 (2019)PubMedPubMedCentral

31.

S. Hanna, B. Khalil, A. Nasrallah, B.A. Saykali, R. Sobh, S. Nasser et al. StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion. Int J. Oncol. 44(5), 1499–511 (2014)PubMedPubMedCentralCrossRef

32.

A. Nasrallah, B. Saykali, S. Al Dimassi, N. Khoury, S. Hanna, M. El-Sibai, Effect of StarD13 on colorectal cancer proliferation, motility and invasion. Oncol. Rep. 31(1), 505–15 (2014)PubMedCrossRef

33.

Z. Huang, Z. Zhang, C. Zhou, L. Liu, C. Huang, Epithelial-mesenchymal transition: the history, regulatory mechanism, and cancer therapeutic opportunities. MedComm (2020). 3(2), e144 (2022)PubMedPubMedCentral

34.

L. Jaafar, Z. Chamseddine, M. El-Sibai, StarD13: a potential star target for tumor therapeutics. Hum. Cell 33(3), 437–443 (2020)PubMedCrossRef

35.

M. Al Haddad, R. El-Rif, S. Hanna, L. Jaafar, R. Dennaoui, S. Abdellatef et al. Differential regulation of rho GTPases during lung adenocarcinoma migration and invasion reveals a novel role of the tumor suppressor StarD13 in invadopodia regulation. Cell Commun. Signal 18(1), 144 (2020)PubMedPubMedCentralCrossRef

36.

Z. Yang, H. Chen, M. Shu, Y. Zhang, L. Xue, Y. Lin, DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway. Oncol. Lett. 17(2), 2107–2116 (2019)PubMed

37.

A.C. Braun, M.A. Olayioye, Rho regulation: DLC proteins in space and time. Cell Signal 27(8), 1643–51 (2015)PubMedCrossRef

38.

D. Bar-Sagi, A. Hall, Ras and Rho GTPases: a family reunion. Cell 103(2), 227–38 (2000)PubMedCrossRef

39.

E. Sahai, C.J. Marshall, RHO-GTPases and cancer. Nat. Rev. Cancer 2(2), 133–42 (2002)PubMedCrossRef

40.

J. Chen, C. Jiang, L. Fu, C.L. Zhu, Y.Q. Xiang, L.X. Jiang et al. CHL1 suppresses tumor growth and metastasis in nasopharyngeal carcinoma by repressing PI3K/AKT signaling pathway via interaction with Integrin beta1 and Merlin. Int J. Biol. Sci. 15(9), 1802–1815 (2019)PubMedPubMedCentralCrossRef

41.

B.D. Khalil, S. Hanna, B.A. Saykali, S. El-Sitt, A. Nasrallah, D. Marston et al. The regulation of RhoA at focal adhesions by StarD13 is important for astrocytoma cell motility. Exp. Cell Res. 321(2), 109–22 (2014)PubMedCrossRef

42.

S. Abdellatef, I. Fakhoury, M.A. Haddad, L. Jaafar, H. Maalouf, S. Hanna et al. StarD13 negatively regulates invadopodia formation and invasion in high-grade serous (HGS) ovarian adenocarcinoma cells by inhibiting Cdc42. Eur. J. Cell Biol. 101(1), 151197 (2022)PubMedCrossRef

43.

M.A. Nieto, R.Y. Huang, R.A. Jackson, J.P. Thiery, Emt: 2016. Cell 166(1), 21–45 (2016)PubMedCrossRef

44.

X. Li, L. Zheng, F. Zhang, J. Hu, J. Chou, Y. Liu et al. STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget 7(17), 23197–211 (2016)PubMedPubMedCentralCrossRef

45.

J. Hu, X. Li, X. Guo, Q. Guo, C. Xiang, Z. Zhang et al. The CCR2 3’UTR functions as a competing endogenous RNA to inhibit breast cancer metastasis. J. Cell Sci. 130(19), 3399–3413 (2017)PubMed

46.

L. Zheng, C. Xiang, X. Li, Q. Guo, L. Gao, H. Ni et al. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J. Hematol. Oncol. 11(1), 72 (2018)PubMedPubMedCentralCrossRef

Titel: Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma
verfasst von: Chuimian Zeng
Hai Li
Weiwei Liang
Junxin Chen
Yilin Zhang
Hanrong Zhang
Haipeng Xiao
Yanbing Li
Hongyu Guan
Publikationsdatum: 04.08.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03468-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma